Janux Therapeutics (NASDAQ:JANX) Price Target Lowered to $58.00 at Guggenheim

Janux Therapeutics (NASDAQ:JANX) had its price objective cut by Guggenheim from $68.00 to $58.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts also recently issued reports about the company. UBS Group downgraded Janux Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $57.00 to $15.00 in a research report on Wednesday, April 15th. Barclays cut Janux Therapeutics from an “overweight” rating to an “underweight” rating and lowered their price objective for the stock from $29.00 to $14.00 in a research report on Monday, April 20th. Truist Financial upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Monday, May 4th. Piper Sandler lowered their price target on Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a report on Friday, January 16th. Finally, Weiss Ratings upgraded Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Janux Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $47.83.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $14.18 on Friday. Janux Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $35.34. The stock has a market capitalization of $864.41 million, a P/E ratio of -7.71 and a beta of 2.58. The company’s 50-day simple moving average is $14.35 and its 200-day simple moving average is $17.45.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.13. The firm had revenue of $3.73 million for the quarter, compared to the consensus estimate of $4.36 million. On average, research analysts forecast that Janux Therapeutics will post -2.34 EPS for the current year.

Institutional Trading of Janux Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC boosted its position in Janux Therapeutics by 13.8% during the fourth quarter. Janus Henderson Group PLC now owns 5,350,453 shares of the company’s stock worth $73,850,000 after acquiring an additional 649,341 shares during the last quarter. State Street Corp raised its position in Janux Therapeutics by 103.8% in the fourth quarter. State Street Corp now owns 3,853,951 shares of the company’s stock valued at $53,185,000 after purchasing an additional 1,962,486 shares during the period. Vanguard Group Inc. lifted its position in Janux Therapeutics by 10.4% in the third quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company’s stock valued at $59,074,000 after buying an additional 227,676 shares during the last quarter. Prosight Management LP boosted its position in shares of Janux Therapeutics by 176.5% during the 4th quarter. Prosight Management LP now owns 2,392,523 shares of the company’s stock worth $33,017,000 after purchasing an additional 1,527,173 shares during the period. Finally, Orbimed Advisors LLC boosted its position in shares of Janux Therapeutics by 10.7% during the fourth quarter. Orbimed Advisors LLC now owns 1,954,426 shares of the company’s stock worth $26,971,000 after buying an additional 188,326 shares during the period. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Key Janux Therapeutics News

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: The company reported a smaller-than-expected quarterly loss of $0.39 per share, beating estimates of a $0.52 loss, which may help support investor sentiment. Press Release
• Neutral Sentiment: Revenue came in at $3.73 million, below analyst expectations of $4.36 million, offsetting some of the earnings beat and limiting the immediate upside reaction.
• Neutral Sentiment: Guggenheim lowered its price target to $58 from $68 but maintained a Buy rating, signaling continued long-term confidence despite trimming expectations.
• Neutral Sentiment: Wedbush cut its target to $36 from $45 and kept an Outperform rating, indicating analysts still see meaningful upside but are becoming more cautious.
• Negative Sentiment: Piper Sandler reduced its target to $26 from $30, though it maintained an Overweight rating, adding to the theme of lower near-term valuation expectations.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.